Table 1 Demographic characteristics, comorbidities, clinical data, treatment and outcomes of the overall sample and each cohort
From: Convalescent plasma treatment for patients of 80 years and older with COVID-19 pneumonia
Overall Cohort (n = 123) | Convalescent Plasma (n = 41) | Control Group (n = 82) | p-value | |
|---|---|---|---|---|
Age, mean (SD) | 86.2 (4.60) | 86.7 (5.02) | 85.9 (4.39) | 0.416 |
Female sex, n (%) | 51 (41.5) | 22 (53.7) | 29 (35.4) | 0.052 |
Comorbidity | ||||
Mental impairment, n (%) | 39 (31.7) | 14 (34.2) | 25 (30.5) | 0.681 |
Hypertension, n (%) | 96 (78.1) | 32 (78.1) | 64 (78.1) | 1.000 |
Diabetes mellitus, n (%) | 38 (30.9) | 9 (22.0) | 29 (35.4) | 0.129 |
Dyslipidemia, n (%) | 59 (48.0) | 17 (41.5) | 42 (51.2) | 0.307 |
Obesity, n (%) | 19 (15.5) | 3 (7.3) | 16 (19.5) | 0.078 |
Cardiovascular disease, n (%) | 63 (51.2) | 18 (43.9) | 45 (54.9) | 0.251 |
CPD, n (%) | 28 (22.8) | 8 (19.5) | 20 (24.4) | 0.543 |
Current or past smoker, n (%) | 24 (19.5) | 8 (19.5) | 16 (19.5) | 1.000 |
Chronic kidney disease, n (%) | 25 (20.3) | 7 (17.1) | 18 (22.0) | 0.526 |
Cancer, n (%) | 34 (27.6) | 13 (31.7) | 21 (25.6) | 0.476 |
LTCF residents, n (%) | 25 (20.3) | 8 (19.5) | 17 (20.7) | 0.874 |
Days from symptom onset to admission (*) | 5 (2–7) | 5 (2–7) | 5 (3–7) | 0.877 |
Days from symptom onset to CP infusion (*) | N/A | 7 (4–10) | N/A | – |
Days from admission to CP infusion (*) | N/A | 1 (0–2) | N/A | – |
SaO2 (mmHg) at admission (+) | 91.8 (0.42) | 92.1 (0.60) | 91.7 (0.56) | 0.606 |
Estimated PaO2/FiO2 at admission (+) | 321.5 (5.70) | 319.9 (8.83) | 322.3 (7.35) | 0.848 |
WHO scale (+) | 3.8 (0.06) | 3.8 (0.09) | 3.8 (0.07) | 1.000 |
Treatment, n (%) | ||||
Anticoagulants | 122 (99.2) | 41 (100) | 81 (98.8) | 0.667 |
Antibiotics | 119 (96.8) | 39 (95.1) | 80 (97.6) | 0.472 |
Glucocorticoids | 100 (81.3) | 32 (78.1) | 68 (82.9) | 0.513 |
Remdesivir | 18 (14.6) | 13 (31.7) | 5 (6.1) | 0.000 |
Tocilizumab | 14 (11.4) | 7 (17.1) | 7 (8.5) | 0.160 |
Anakinra | 2 (1.6) | 1 (2.4) | 1 (1.2) | 0.557 |
Lopinavir/ritonavir | 1 (0.8) | 1 (2.4) | 0 (0.0) | 0.333 |
Outcomes | ||||
In-hospital mortality, n (%) | 28 (22.7) | 6 (14.6) | 22 (26.8) | 0.131 |
ICU admission, n (%) | 9 (7.3) | 2 (4.9) | 7 (8.5) | 0.467 |
LoS, discharged, median (IQR) | 11 (9–16) | 11 (9–16) | 11 (7.5–16) | 0.073 |
LoS, dead, median (IQR) | 9 (6–12) | 11 (7–22) | 8.5 (5–12) | 0.067 |